Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery

Status unconfirmed · Phase 4

Conditions studied: Acute Kidney Injury

In brief

This is a randomized, open label study to investigate vasopressin versus phenylephrine as a first line pressor in cardiac surgery. All patients \>18 years of age presenting for coronary artery bypass graft (CABG), valve surgery, or combined CABG and valve surgery will be screened for inclusion. Patients with ejection fraction \< 35%, \> moderate pulmonary hypertension, \> mild right ventricular dysfunction, a planned radial arterial graft, or circulatory arrest will be excluded. Patients will be randomized to receive either vasopressin or phenylephrine as the first line vasopressor during the perioperative period to maintain mean arterial blood pressure \>65 mmhg. Primary outcome is acute kidney injury. Secondary outcomes are 30-day mortality, stroke, myocardial infarction, re-operation, sternal infection, atrial fibrillation, intensive care unit length of stay, and total vasopressor hours.

Key facts

Study ID

NCT04602767

Run by

Thomas Jefferson University

People needed

300

Starts

2020-10-15

Expected to finish

2024-10-01

Last updated by the study team

2024-03-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• >18 years of age
• Coronary artery bypass graft (CABG), valve, or combined CABG and valve surgery

You may not qualify if…

• Ejection fraction < 35%
• > moderate pulmonary hypertension
• > mild right ventricular dysfunction
• Radial arterial graft
• Circulatory arrest

Where it is running

• Thomas Jefferson Univesity — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.